{"id":"acetohexamide","rwe":[],"tags":[{"label":"acetohexamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"A10BB31","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Lilly","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/atenolol","drug":"atenolol","action":"Monitor closely","effect":"May interact with Atenolol","source":"DrugCentral","drugSlug":"atenolol"},{"url":"/drug/betaxolol","drug":"betaxolol","action":"Monitor closely","effect":"May interact with Betaxolol","source":"DrugCentral","drugSlug":"betaxolol"},{"url":"/drug/bisoprolol","drug":"bisoprolol","action":"Monitor closely","effect":"May interact with Bisoprolol Fumarate","source":"DrugCentral","drugSlug":"bisoprolol"},{"url":"/drug/carteolol","drug":"carteolol","action":"Monitor closely","effect":"May interact with Carteolol","source":"DrugCentral","drugSlug":"carteolol"},{"url":"/drug/ciprofloxacin","drug":"ciprofloxacin","action":"Monitor closely","effect":"May interact with Ciprofloxacin","source":"DrugCentral","drugSlug":"ciprofloxacin"},{"url":"/drug/gatifloxacin","drug":"gatifloxacin","action":"Monitor closely","effect":"May interact with Gatifloxacin","source":"DrugCentral","drugSlug":"gatifloxacin"},{"url":"/drug/labetalol","drug":"labetalol","action":"Monitor closely","effect":"May interact with Labetalol","source":"DrugCentral","drugSlug":"labetalol"},{"url":"/drug/levofloxacin","drug":"levofloxacin","action":"Monitor closely","effect":"May interact with Levofloxacin","source":"DrugCentral","drugSlug":"levofloxacin"},{"url":"/drug/metoprolol","drug":"metoprolol","action":"Monitor closely","effect":"May interact with Metoprolol","source":"DrugCentral","drugSlug":"metoprolol"},{"url":"/drug/nadolol","drug":"nadolol","action":"Monitor closely","effect":"May interact with Nadolol","source":"DrugCentral","drugSlug":"nadolol"},{"url":"/drug/norfloxacin","drug":"norfloxacin","action":"Monitor closely","effect":"May interact with Norfloxacin","source":"DrugCentral","drugSlug":"norfloxacin"},{"url":"/drug/ofloxacin","drug":"ofloxacin","action":"Monitor closely","effect":"May interact with Ofloxacin","source":"DrugCentral","drugSlug":"ofloxacin"},{"url":"/drug/penbutolol","drug":"penbutolol","action":"Monitor closely","effect":"May interact with Penbutolol","source":"DrugCentral","drugSlug":"penbutolol"},{"url":"/drug/pindolol","drug":"pindolol","action":"Monitor closely","effect":"May interact with Pindolol","source":"DrugCentral","drugSlug":"pindolol"},{"url":"/drug/propranolol","drug":"propranolol","action":"Monitor closely","effect":"May interact with Propranolol","source":"DrugCentral","drugSlug":"propranolol"},{"url":"/drug/sotalol","drug":"sotalol","action":"Monitor closely","effect":"May interact with Sotalol","source":"DrugCentral","drugSlug":"sotalol"},{"url":"/drug/timolol","drug":"timolol","action":"Monitor closely","effect":"May interact with Timolol","source":"DrugCentral","drugSlug":"timolol"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Eli Lilly","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACETOHEXAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:47:27.932966+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Acetohexamide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:47:34.875666+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:47:33.459676+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETOHEXAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:47:33.748347+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:47:34.875608+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1589/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:47:34.527295+00:00"}},"allNames":"dymelor","offLabel":[],"synonyms":["dymelor","acetohexamide","acetohexamid"],"timeline":[{"date":"1964-12-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Lilly)"},{"date":"1987-02-09","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Dymelor (acetohexamide) is a small molecule drug developed by Lilly that targets the sulfonylurea receptor 1, Kir6.2. It is classified as an acetohexamide and was approved by the FDA in 1964 for the treatment of type 2 diabetes mellitus. Dymelor is now off-patent and has multiple generic manufacturers. As a sulfonylurea, it works by stimulating insulin release from the pancreas. It is no longer under patent protection, making it available as a generic medication.","brandName":"Dymelor","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"},{"name":"bexagliflozin","slug":"bexagliflozin","company":"Theracosbio Llc"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","novelty":"Follow-on","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"}],"modality":"Small Molecule","drugClass":"acetohexamide","explanation":"","oneSentence":"","technicalDetail":"Dymelor binds to the sulfonylurea receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel (K_ATP), which is composed of Kir6.2 and SUR1. This binding causes a conformational change in the channel, leading to its closure and an increase in intracellular ATP levels. The increase in ATP levels inhibits the K_ATP channel, leading to membrane depolarization and an influx of calcium ions, which ultimately triggers the release of insulin from the pancreas."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acetohexamide","title":"Acetohexamide","extract":"Acetohexamide is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone."},"commercial":{"launchDate":"1964","_launchSource":"DrugCentral (FDA 1964-12-23, LILLY)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/57","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACETOHEXAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETOHEXAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Acetohexamide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:23:09.210376","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:36.193742+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"acetohexamide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":714582,"completionDate":"2018-06-25"},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance"],"enrollment":246,"completionDate":"2010-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000145888","MMSL":"4123","NDDF":"000907","UNII":"QGC8W08I6I","VUID":"4017503","CHEBI":"CHEBI:28052","VANDF":"4017503","INN_ID":"1134","RXNORM":"173","UMLSCUI":"C0000992","chemblId":"CHEMBL1589","ChEMBL_ID":"CHEMBL1589","KEGG_DRUG":"D00219","DRUGBANK_ID":"DB00414","PUBCHEM_CID":"1989","SNOMEDCT_US":"387210001","IUPHAR_LIGAND_ID":"6793","MESH_DESCRIPTOR_UI":"D000092"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1964-","companyName":"Eli Lilly","relationship":"Original Developer"}],"publicationCount":220,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB31","allCodes":["A10BB31"]},"biosimilarFilings":[],"originalDeveloper":"Lilly","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Usl Pharma","Watson Labs Teva"],"status":"approved","companyName":"Eli Lilly","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"1964","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:36.193742+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}